
Copyright:

© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI link to article:

https://doi.org/10.1093/ckj/sfx081

Also available at:

https://academic.oup.com/ckj/article/10/5/600/4283135/Complement-C5-inhibiting-therapy-for-the

Date deposited:

02/10/2017

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea

Vicky Brocklebank and David Kavanagh

The National Renal Complement Therapeutics Centre (NRCTC), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Correspondence and offprint requests to: David Kavanagh; E-mail: david.kavanagh@ncl.ac.uk

Abstract

Thrombotic microangiopathy (TMA), characterized by organ injury occurring consequent to severe endothelial damage, can manifest in a diverse range of diseases. In complement-mediated atypical haemolytic uraemic syndrome (aHUS) a primary defect in complement, such as a mutation or autoantibody leading to over activation of the alternative pathway, predisposes to the development of disease, usually following exposure to an environmental trigger. The elucidation of the pathogenesis of aHUS resulted in the successful introduction of the complement inhibitor eculizumab into clinical practice. In other TMAs, although complement activation may be seen, its role in the pathogenesis remains to be confirmed by an interventional trial. Although many case reports in TMAs other than complement-mediated aHUS hint at efficacy, publication bias, concurrent therapies and in some cases the self-limiting nature of disease make broader interpretation difficult. In this article, we will review the evidence for the role of complement inhibition in complement-mediated aHUS and other TMAs.

Key words: atypical haemolytic uraemic syndrome, complement, eculizumab, thrombotic microangiopathy

Introduction

Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic haemolytic anaemia and organ injury [1], and can manifest in a diverse range of diseases. There is overlap in the pathogenic mechanisms involved in the different TMAs, and as a consequence classification is challenging. The introduction into clinical practice of complement-inhibiting therapy has stimulated particular interest into the role that complement plays. The prognosis of individuals with complement-mediated atypical haemolytic uraemic syndrome (aHUS), a term that we apply here specifically to individuals with TMA caused by a primary defect in the complement system that results in dysregulation, has been transformed by the terminal complement inhibitor eculizumab. This paradigm shift has understandably led to the question: who else with a TMA might benefit from this treatment? In this review, we will consider the contribution of complement dysregulation (resulting from a primary defect) and complement activation (as a secondary effect) to the pathogenesis of the different TMAs, and evaluate the strength of the evidence supporting clinical benefit of complement-inhibiting therapy. There has never been a randomized controlled trial (RCT) that demonstrates efficacy of complement-inhibiting therapy in any TMA. Complement has important physiological roles, for example in the immune system...
defence against encapsulated organisms, so complement inhibition does not come without potential for significant harm; appropriate selection of individuals who are likely to benefit from therapy is therefore paramount.

**Complement**

The complement system comprises >30 plasma and cell surface-bound proteins that operate in a regulated network of signalling and amplification [2]. It functions to protect the host against infection, by stimulating the inflammatory response and opsonizing and lysing pathogens as a fundamental component of the innate immune system, as well as modulating the adaptive immune system; it also facilitates the disposal of damaged host cells and potentially injurious immune complexes [3]. Complement can be initiated by three pathways (Figure 1): in the classical pathway, pattern recognition molecules such as immunoglobulins are recognized by C1q, and in the lectin pathway mannose-binding lectin (MBL) recognizes pathogen-associated carbohydrates; these pathways generate the C3 convertase C4b2b. The alternative pathway can be initiated by pattern recognition molecules, but in addition is constitutively active, with spontaneous hydrolysis (tickover) of C3 leading to it interacting with factor B (FB) to generate the C3 convertase C3bBb, and the pathways converge in the amplification loop, in which C3 is cleaved and activated by C3bBb. This leads to C5 cleavage, and results in the production of anaphylatoxins and activation of the terminal pathway, which initiates the assembly of the cell-lysing membrane attack complex (MAC). The amplification loop allows for rapid response to pathogens, but leaves the host vulnerable to bystander damage if the tick over component is unchecked. The system is therefore tightly regulated by plasma and cell surface proteins; for the alternative pathway the most important are factor H (FH), factor I (FI) and membrane cofactor protein (MCP, CD46). Rarely, complement dysregulation due to a defect in a component or regulator can directly cause disease, and commonly, in many diseases, tissue damage activates complement, which intensifies the inflammation [4]. Consequently, there has been much interest and investment in developing complement-targeted therapy [5].

**Complement-inhibiting therapy**

The complexity of the complement system means that there are multiple potential therapeutic targets: drugs that target the activation pathways, the anaphylatoxins, the amplification loop and the terminal pathway have been developed and have entered preclinical and clinical trials [5]. Alexion Pharmaceuticals developed in the 1990s a recombinant humanized monoclonal antibody that functionally blocked C5 [6], and this agent, named eculizumab (Soliris), entered early clinical trials for a range of inflammatory conditions [5, 7]. Trials of eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PNH), a disease characterized by complement-mediated intravascular haemolysis and caused by a somatic mutation that results in disruption of erythrocyte complement regulation, yielded the most impressive efficacy [8, 9] and eculizumab was approved for use in PNH in 2007 by the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) [10]. Because genetic and functional analysis had also identified aHUS as a disease caused by complement dysregulation, the PNH breakthrough encouraged the use of eculizumab in patients with complement-mediated aHUS; promising case reports [11, 12] were followed by successful clinical trials [13] and it was approved by the FDA and EMA for use in complement-mediated aHUS in 2011 [10].

![Complement activation, regulation and therapeutic intervention](https://academic.oup.com/ckj/article-abstract/10/5/600/4283135/Complement-C5-inhibiting-therapy-for-the)
Potential complications of complement-inhibiting drugs

The terminal complement pathway is fundamental to the immune response against encapsulated organisms, so the major concern with terminal complement inhibition is infection, and individuals deficient in terminal complement components are particularly susceptible to Neisseria infections [10, 14]. Disseminated gonococcal infection has been reported in patients treated with eculizumab, and the risk of meningococcal infection is increased by up to 10,000 times by treatment with eculizumab [14]. For this reason meningococcal vaccination and antibiotic prophylaxis is recommended in patients receiving eculizumab [15], though meningococcal infection can still occur despite these measures [16, 17].

There may be other infectious associations: respiratory tract infections are reported to be more common in patients on eculizumab compared with placebo [14], and a case of progressive multifocal leucoencephalopathy, an opportunistic infection of the CNS caused by reactivation of the polyomavirus JC, was recently reported in a patient treated with eculizumab, though they had also received multiple immunosuppressants [18].

In addition to infection complications, other concerns may emerge as use of complement-inhibiting therapy in clinical practice increases. Eculizumab-associated hepatotoxicity has been reported in children [19], and glomerular deposition of eculizumab in individuals with C3 glomerulopathy (C3G) [20], though not complement-mediated aHUS [21], has been reported although the long-term clinical consequences are as yet unclear.

TMAs

TMAs are the consequences of severe endothelial injury with pathological features representing the tissue response to injury [15]. TMAs are characterized by thrombocytopenia (due to aggregation and consumption of platelets), microangiopathic haemolytic anaemia (haemolysis consequent to mechanical injury to erythrocytes in partially occluded vessels) and organ injury (ischaemia) [1]. They can manifest in a diverse range of diseases and result in a range of clinical presentations, though they commonly comprise acute kidney injury (AKI) due to the apparent propensity of the glomerular circulation to endothelial damage and occlusion.

The classification and nomenclature of the TMAs can be challenging. Thrombotic thrombocytopenic purpura (TTP) refers to individuals with ADAMTS13 activity <5%, and Shiga toxin-producing Escherichia coli-associated HUS is defined as STEC-HUS. The term atypical haemolytic uraemic syndrome (aHUS) has broadly been used to describe any TMA that was not TTP or STEC-HUS, thus describing a heterogeneous mixture of conditions. There is a move towards using the term ‘complement-mediated aHUS’ to define those individuals with a complement abnormality as the primary underlying pathology, to distinguish them from individuals with TMA consequent to an underlying disorder; this is important because it may help guide therapeutic strategies [22, 23]. However, this distinction is not unequivocal: it is well recognized that complement gene mutations exhibit variable penetrance, and individuals with a genetic predisposition usually require an environmental trigger for TMA to manifest [3]. Conversely, in cases of TMA where no genetic or acquired complement abnormality is found, complement can be seen to be activated and may play a role in pathogenesis (Figure 2). TMA diagnosis, classification and treatment decisions are difficult; there may be no definitive diagnostic test, and no refined methods of monitoring disease activity or therapeutic response beyond crude tests of haemolysis parameters and organ recovery [24].

Evidence for the role of complement in the TMAs

Complement-mediated aHUS

The pathogenesis of complement-mediated aHUS is archetypal for diseases occurring due to over activation of the complement system. Ever since 1998, when genetic studies first produced molecular evidence that CFH mutations are associated with complement-mediated aHUS [25], there have been major advances in the understanding of the pathogenesis. Genetic studies and functional analysis in individuals, families and large cohorts [26, 27] have identified pathogenic activating mutations in the genes encoding the alternative pathway components C3 and CFH, and loss of function mutations in the genes encoding the alternative pathway regulators CFH, CFI and CD46 [3, 28–30]. A mutation is identified in ~60% of individuals [23]. Autoantibodies that bind to FH [31, 32] and FI [33] resulting in complement dysregulation [34] have also been identified in 5–56% of individuals with complement-mediated aHUS [35]. Even in those individuals with a complement mutation or autoantibody a trigger, for example infection or pregnancy, is frequently required for disease to manifest [3].

The evidence that this disease is mediated by a primary complement defect is strong, so there is mechanistic rationale for complement-inhibiting therapy, though there has never been an RCT. The landmark trials of eculizumab for complement-mediated aHUS published in 2013 [13] were single-arm studies; however, given the high morbidity and mortality in individuals with complement abnormalities [3– to 5-year survival without established renal failure (ERF) of 52–64% in children and 33–36% in adults, even with plasma exchange (PEX) [26, 27]], it is accepted that comparison with historical controls is justified. The positive results (Table 1) paved the way for the first-line use of eculizumab in clinical practice, and its efficacy has been validated in subsequent prospective studies [37–39] and cohort analysis [42]. The prognosis of complement-mediated aHUS has been transformed: full recovery of renal function is now expected, other than in those who present late in the course of disease. Kidney Disease: Improving Global Outcomes (KDIGO) recommends that all patients with a clinical diagnosis of complement-mediated aHUS are eligible for treatment with a complement inhibitor [15]. International consensus recommendations are that in children with a clinical diagnosis of complement-mediated aHUS, eculizumab (or PEX if eculizumab is not available) should be started within 24–48 h (results of complement genetic tests are not required for this decision) [290].

More recently, with increased use in clinical practice, it has become clear that not all patients respond to eculizumab [94, 263]; in a non-randomized, uncontrolled trial of eculizumab in children, improvement in renal function was seen in all patients with a complement mutation or autoantibody, but not in 27% of those without an identified complement abnormality [39, 291]. The initial trials in adults included a higher proportion of patients with mutations than is seen in clinical practice. Further research is therefore required to inform a stratified approach to treatment [292] and it may be that the most clinically relevant classification would differentiate eculizumab responsive and eculizumab-resistant aHUS.

Prophylaxis and recurrence of complement-mediated aHUS after kidney transplantation

The outcomes of kidney transplantation in patients with complement-mediated aHUS were historically very poor: a retrospective
analysis reported recurrence of 68%, and 5-year death-censored graft survival of 51% [63]; even if patients with recurrence were treated with PEX, 59% of grafts failed [65]. The genetic background predicts the risk of recurrence and graft failure: rates of >70% have been reported in individuals with CFH mutations, but the risk is very low if the mutation is in CD46 [64, 293]. Some patients were therefore considered ‘untransplantable’. One option was combined liver and kidney transplantation, but experience is very limited internationally and short-term risk is significant: for 20 published cases, the success rate was 80% but the mortality rate was 15% [55]. There are no trials that specifically examine the use of eculizumab for prophylaxis or for treatment of recurrence in kidney transplantation, although the single-arm eculizumab trials included small number of adults [13, 37, 38] and children [39] with prior kidney transplant, and reported efficacy. Retrospective cohort analyses have reported successful use of eculizumab to facilitate transplantation [42–44] and to treat recurrence [43], and there are multiple case reports (Table 1). Again, despite the lack of RCT evidence, the favourable results with eculizumab compared with historical outcomes are felt to justify that prophylactic eculizumab is now the gold standard approach to kidney transplantation in those with a high-risk genetic background.

De novo TMA after transplantation

In kidney transplant recipients, the incidence of de novo TMA has been reported as 0.8% in the United States Renal Data System (USRDS) [294], but single-centre studies report incidences of up to 14% [295]. Multiple associations and risk factors have been observed, including viral infections such as cytomegalovirus (CMV), immunosuppressant drugs such as calcineurin inhibitors (CNIs) and sirolimus [295], and antibody-mediated rejection (AMR) [72]. These factors, together with ischaemia-reperfusion injury, create an ‘endothelial damaging milieu’ that transplant recipients are exposed to [296], and it is not clear to what extent complement is involved. Underlying complement mutations may play a role especially where the initial cause of end-stage renal failure was unclear. In one cohort analysis, mutations were identified in 29% of patients with de novo post-transplant TMA [66]. Evidence regarding management is also limited; good
Table 1. Evidence for the role of complement in the TMAs

<table>
<thead>
<tr>
<th>TMA</th>
<th>Evidence for complement involvement in pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complement-mediated aHUS</td>
<td>• 2 large aHUS cohorts (&gt;200 patients): complement gene mutation identified in 48–60% [26, 27]; functional significance of mutations in CFH, CFI, CD46, C3, CFB demonstrated [3].</td>
<td>• No RCTs. • 3 prospective, single-arm, phase 2 trials of eculizumab in adults: 88% TMA event-free status and 76% &gt;25% improvement in sCr at 2 years in 17 patients with progressive TMA and renal impairment; complement mutation/anti-FH Ab in 76% [13, 37]. • 95% TMA event-free status and 55% &gt;25% improvement in sCr at 2 years in 20 patients with stable TMA and renal impairment; complement mutation/anti-FH Ab in 70% [13, 37]. • Complete TMA response at 26 weeks in 73% in 41 patients. 2 cases of meningococcal infection. Complement mutation/anti-FH Ab in 49% [38]. • 1 prospective, single-arm, phase 2 trial of eculizumab in 22 children: complete TMA response in 64% at 26 weeks; &gt;25% improvement in sCr in 73%; complement mutation/anti-FH Ab in 50%. No deaths/meningococcal infection [39].</td>
<td>High morbidity and mortality prior to eculizumab availability, best available treatment was PEX: • Retrospective analysis of 2 large cohorts: 5-year survival without ERF 64% in children and 36% in adults (214 patients); worst prognosis with CFH mutations: 50% ERF at first episode despite high intensity PEX [26]. 3-year survival without ERF 52% in children and 33% in adults (273 patients); 23% if CFH mutation, 6% if CFI mutation. Complete remission with PEX in 5% with CFH mutation 27]. • Review of all published case series of patients (278 patients) with anti-FH Ab: ERF in 27–63% [40]. • 2 case reports of isolated liver transplant in patients with CFH mutation: 1 successful, 1 fatal [41].</td>
</tr>
<tr>
<td>Kidney transplant</td>
<td>Complement-mediated aHUS prophylaxis</td>
<td>As above.</td>
<td>• Successful use of eculizumab to facilitate transplantation without recurrence reported in retrospective cohort analyses [42–44]. • Case reports of successful use of eculizumab with [45, 46] and without [47–54] PEX.</td>
</tr>
<tr>
<td>Complement-mediated aHUS recurrence</td>
<td>As above.</td>
<td>• No RCTs or trials specific to transplant recurrence. • The prospective, single-arm, phase 2 trials of eculizumab included some patients with prior kidney transplant (total 24 adults [13, 37, 38] and 2 children [39]) and reported efficacy. • Retrospective cohort analysis included 13 patients treated with eculizumab for recurrence: all responded. The delay of eculizumab initiation after TMA onset inversely correlated with the degree of renal function improvement [43].</td>
<td>• Retrospective review of 57 patients (71 transplants); 68% had a complement mutation. 68% aHUS recurrence. 7% mortality. 1- and 5-year post-transplantation death-censored graft survival were 76% and 51%. Preemptive PEX reduced graft loss but disease-driven PEX did not [63]. • Review of 100 kidney transplants: CFH mutation 73.7% recurrence, 77.8% graft failure; CFI mutation: 100% recurrence, 100%</td>
</tr>
</tbody>
</table>

(continued)
### Table 1. (continued)

<table>
<thead>
<tr>
<th>TMA</th>
<th>Evidence for complement involvement in pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
<tbody>
<tr>
<td>De novo TMA</td>
<td>• Genetic analysis in 24 patients with de novo TMA after transplantation identified CFH or CFI mutation in 29% [66].</td>
<td>• Case reports of successful use of eculizumab [57–62].</td>
<td>graft failure; CD46 mutation: no recurrence/graft failure [64].</td>
</tr>
<tr>
<td>AMR-associated TMA</td>
<td>• No evidence specific to AMR with TMA.</td>
<td>Case reports of eculizumab for AMR with TMA:</td>
<td>Case series: 29 patients with de novo TMA treated with discontinuation of CNI and PEX: graft survival rate was 80% [72].</td>
</tr>
<tr>
<td></td>
<td>• C4d deposition in peritubular capillaries suggests classical complement pathway activation [76].</td>
<td>• TMA resolved, but graft failed of BKV nephropathy [77].</td>
<td>Case reports of TMA resolution following immunosuppression switch, CNI to belatacept [73] or everolimus [74].</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• TMA resolved but ongoing AMR [78].</td>
<td>• 2 cases of TMA following FAK transplant successfully treated with PEX and immunosuppression switch [75].</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Successful use (concurrent with other treatment) [79, 80].</td>
<td>• Therapeutic strategies for AMR (not specific to AMR with TMA) include PEX, IVIG and rituximab, but there is insufficient evidence to determine optimal treatment [92].</td>
</tr>
</tbody>
</table>

Trials of eculizumab for treatment of AMR (not specific to TMA related):
- Eculizumab to prevent AMR in patients with a positive cross match against their live donor: 26 patients compared with historical cohort of 51 patients; single-centre, open label. ClinicalTrials.gov Identifier: NCT006707 Eculizumab reduced acute AMR episodes but did not prevent chronic AMR [81, 82].
- Pilot RCT of eculizumab for chronic AMR: no significant difference, but underpowered [83].
- Case reports/series of successful [84–87], unsuccessful [88] and mixed success [89–91] in use of eculizumab for AMR (no TMA), concurrent with other treatment in most cases.
<table>
<thead>
<tr>
<th>TMA</th>
<th>Evidence for complement involvement in pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
</table>
| DGKE-associated aHUS                          | • No evidence for complement involvement in pathogenesis.  
• DGKE silencing in endothelial cells does not induce complement deposition in vitro [93]. | Only a small number of cases have been published:  
• Cohort of 13: 1/7 treated with eculizumab relapsed while on treatment. All developed progressive CKD/ERF [94].  
• 4 cases; 1 treated with eculizumab and responded—but had concomitant C3 mutation [95]. | • 5 patients; multiple relapses, treated supportive or with PI/PEX. Normal renal function in all at last follow-up [96].  
• 2 cases, responded to PI [97]. |
| TTP                                           | • Mouse model: C3 deposition in kidneys [98].  
• In vitro: TTP serum caused C3 and MAC deposition on HMEC-1; cytotoxic effect was abolished by complement inhibition [99]. | • Case report of efficacy of eculizumab in TTP case refractory to PEX, corticosteroids, rituximab, NAC and vincristine. However, a later update reported positive Anti-FH Ab, and ADAMTS13 not sufficiently low [106, 107].  
• Case report, efficacy of eculizumab in a child with congenital TTP (ADAMTS13 mutation) and no complement gene abnormality/anti-FH Ab [108]. | • American society of apheresis guidelines: grade IA evidence for PEX as first-line treatment: PEX decreased mortality from universally fatal to < 10%. 7 RCTs (301 patients) [109].  
• Phase 2 studies demonstrate efficacy of rituximab in preventing relapse in acquired TTP [110–112]: 10% relapse compared with 57% in historical controls [110].  
• Phase 2 study of caplacizumab (monoclonal antibody against vWF) versus placebo in addition to PEX + immunosuppression in acquired TTP more rapid resolution of TMA [113]. |
| Pregnancy associated Complement-mediated aHUS | Genetics: cohort of 21 females with pregnancy-associated aHUS (P-aHUS): 86% had a complement gene mutation [114]. | 2 case reports of successful use of eculizumab in P-aHUS in context of mutations in CFH [115] and CFI [116].  
No published reports. | In the cohort of 21 with P-aHUS, 83% were treated with PEX (none received eculizumab): 76% developed ERF [114].  
UK cohort of pregnancy-associated TTP.  
Congenital TTP: fetal survival 58% for index presentation, and 100% if actively managed. Acquired TTP: fetal survival 58% [117].  
Clinical studies have reported complete biochemical resolution rates of 29–43% with expectant management of severe pre-eclampsiaHELLP, but fetal/neonatal mortality of 14–20% [128]. |
| TTP                                           | In vitro: eculizumab plus HELLP serum resulted in less cell killing [118]. | 75 pregnancies in 61 women on eculizumab for PNH: 8% developed pre-eclampsia [126].  
5 pregnancies in 3 women with complement-mediated aHUS on eculizumab: 2 women experienced pre-eclampsia and 1 HELLP despite complement inhibition [127].  
• Case report of eculizumab use in addition to expectant management for HELLP at 26 weeks gestation: delivery delayed until 29 weeks [128]. | • 75 pregnancies in 61 women on eculizumab for PNH: 8% developed pre-eclampsia [126].  
5 pregnancies in 3 women with complement-mediated aHUS on eculizumab: 2 women experienced pre-eclampsia and 1 HELLP despite complement inhibition [127].  
• Case report of eculizumab use in addition to expectant management for HELLP at 26 weeks gestation: delivery delayed until 29 weeks [128]. |
| HELLP                                         | In vitro: eculizumab plus HELLP serum resulted in less cell killing [118]. | • 75 pregnancies in 61 women on eculizumab for PNH: 8% developed pre-eclampsia [126].  
5 pregnancies in 3 women with complement-mediated aHUS on eculizumab: 2 women experienced pre-eclampsia and 1 HELLP despite complement inhibition [127].  
• Case report of eculizumab use in addition to expectant management for HELLP at 26 weeks gestation: delivery delayed until 29 weeks [128]. | • 75 pregnancies in 61 women on eculizumab for PNH: 8% developed pre-eclampsia [126].  
5 pregnancies in 3 women with complement-mediated aHUS on eculizumab: 2 women experienced pre-eclampsia and 1 HELLP despite complement inhibition [127].  
• Case report of eculizumab use in addition to expectant management for HELLP at 26 weeks gestation: delivery delayed until 29 weeks [128]. |

(continued)
<table>
<thead>
<tr>
<th>TMA</th>
<th>Evidence for complement involvement in pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic (cobalam in C deficiency)</td>
<td>Genetics:</td>
<td>Case series of 36 patients: 2 received eculizumab and did not respond [129].</td>
<td>Case series of 36 patients: 54% had clinical recovery with metabolic therapy. Mortality 100% in untreated group, 44% overall, 79% in group with cardiopulmonary involvement [129].</td>
</tr>
<tr>
<td></td>
<td>• Concomitant anti-FH Ab (patient died) and CFH mutation (patient responded to PEX) in one cohort with established cbClC defect [129].</td>
<td>Case report: a dult presenting with TMA, dialysis dependent. No response to eculizumab. Subsequently found to have MMACHC mutation [130].</td>
<td>Natural history is of good prognosis. Long-term outcome data: 70% fully recover, 3% develop ERF, 9–18% develop CKD [150].</td>
</tr>
<tr>
<td></td>
<td>• Child with aHUS attributed to CD46 mutation; died after renal transplantation from pulmonary veno-occlusive disease; subsequently found to have MMACHC mutation [130].</td>
<td>• Case series of 36 patients: 2 received eculizumab and did not respond [129].</td>
<td>• American Society of Apheresis guidelines: PEX in STEC-HUS is grade 2C category III (and grade 1C category IV if absence of severe neurological symptoms) [109].</td>
</tr>
<tr>
<td></td>
<td>• Case report: 2 sisters with cbClC deficiency; 1 also had CFH mutation, and had more severe disease, though both responded to metabolic therapy [131].</td>
<td>• Case report: a dult presenting with TMA, dialysis dependent. No response to eculizumab. Subsequently found to have MMACHC mutation [130].</td>
<td>• Prospective non-controlled trial 12 patients in 2011 O104:H4 outbreak treated with IgG immunoadsorption and IgG replacement. 8 patients also received eculizumab. No deaths. Complete renal and neurological recovery in 10/12 [151].</td>
</tr>
<tr>
<td>Infection associated</td>
<td>Mouse models:</td>
<td>Ongoing RCT: eculizumab in Shiga toxin-related HUS pediatric patients. ClinicalTrials.gov Identifier: NCT02205541 Retrospective analysis of the 2011 O104:H4 outbreak:</td>
<td>• Natural history is of good prognosis. Long-term outcome data: 70% fully recover, 3% develop ERF, 9–18% develop CKD [150].</td>
</tr>
<tr>
<td>STEC</td>
<td>• In vitro and in vivo experiments demonstrated Stx-induced complement activation and C3a-dependent microvascular thrombosis (via P-selectin) [133].</td>
<td>• 491 registry patients. Compared best supportive care (57 patients, 12%), PEX (241 patients, 49%) and PEX + eculizumab (193 patients, 39%). Direct comparison not possible because patients who received eculizumab had more severe illness. Mortality was 10.5% for best supportive care, 3.7% for PEX and 2.6% for PEX + eculizumab—no statistical significance between PEX and PEX + eculizumab. Median creatinine at the time of discharge was lowest in best supportive care group. Concluded that the data did not support a beneficial role of eculizumab [147].</td>
<td>• American Society of Apheresis guidelines: PEX in STEC-HUS is grade 2C category III (and grade 1C category IV if absence of severe neurological symptoms) [109].</td>
</tr>
<tr>
<td></td>
<td>• MBL2 inhibition protected against complement activation and renal injury induced by Stx2 [134].</td>
<td>• Stx2-induced activation of the alternative complement pathway results in podocyte injury [135].</td>
<td>• Prospective non-controlled trial 12 patients in 2011 O104:H4 outbreak treated with IgG immunoadsorption and IgG replacement. 8 patients also received eculizumab. No deaths. Complete renal and neurological recovery in 10/12 [151].</td>
</tr>
<tr>
<td></td>
<td>• Stx2 binds to FH and delays cofactor activity [136].</td>
<td>• Stx2 to CFHR1 and competes with FH for Stx2 binding, with resultant reduction in FH cofactor activity [137].</td>
<td>2009 systematic review: 7 RCTs in 476 children (no distinction between STEC-HUS and aHUS; &gt;70%, were diarrhea associated cases). No advantage over supportive care was identified for FFP, anticoagulation, steroids and Shiga toxin-binding agent [152].</td>
</tr>
<tr>
<td></td>
<td>• Stx2 binds to CFHR1 and competes with FH for Stx2 binding, with resultant reduction in FH cofactor activity [137].</td>
<td>• Stx and O157LPS induced the release of microparticles with surface-bound C3 and C9 [138].</td>
<td>Retrospective analysis of 90 children with STEC-HUS in the 2011 O104:H4 outbreak. 74% received supportive care only. 10 received PEX, 6 eculizumab and 7 received both. 71% required dialysis. Mortality was 1%. At 4 months follow-up 94% had normal renal function, 1% remained on dialysis and 3% had CKD3/4 [153].</td>
</tr>
<tr>
<td></td>
<td>• Stx2-induced complement-mediated haemolysis [139].</td>
<td>• Stx2-induced complement-mediated haemolysis [139].</td>
<td>• Role of PEX controversial; theoretical risk of worsening the TMA with donor plasma because it may contain anti-T IgM [158].</td>
</tr>
<tr>
<td></td>
<td>• Observational clinical data: elevated C5b-9 levels [140–142].</td>
<td>• Observational clinical data: elevated C5b-9 levels [140–142].</td>
<td>• American Society of Apheresis guidelines: PEX in pneumococcal HUS: grade 2C, category III recommendation [109].</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>Genetics:</td>
<td>Case report: child with pneumococcal HUS treated with eculizumab due to lack of response to supportive care: recovered renal function (dialysis for 30 days) [156].</td>
<td>• Mouse model: suggests that the interaction between pneumococcal surface protein C (PspC) and FH contributes to pneumococcal virulence [154].</td>
</tr>
<tr>
<td></td>
<td>• Case reports of complement gene mutations in STEC-HUS [140, 143–145].</td>
<td>Case report: child with pneumococcal HUS treated with eculizumab due to lack of response to supportive care: recovered renal function (dialysis for 30 days) [156].</td>
<td>• Hypothesis: that the cleavage of sialic acid residues by pneumococcal produced neuraminidase results in disruption of the binding of FH/C5b, and therefore a function FH deficit at the cell surface [155].</td>
</tr>
<tr>
<td></td>
<td>• Complement gene variant in 7/25 STEC-HUS cases [146].</td>
<td></td>
<td>• Role of PEX controversial; theoretical risk of worsening the TMA with donor plasma because it may contain anti-T IgM [158].</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• American Society of Apheresis guidelines: PEX in pneumococcal HUS: grade 2C, category III recommendation [109].</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>TMA</th>
<th>Evidence for complement involvement in pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>• Observational clinical data: case reports/series have reported transient low C3 and complement gene mutations [156, 157].</td>
<td>Case report: TMA in a patient non-compliant with HAART; treated with PEX and eculizumab and recovered (HAART also presumably restarted) [159].</td>
<td>• Death usually results from the complications of pneumococcal infection [155].</td>
</tr>
<tr>
<td></td>
<td>No evidence.</td>
<td></td>
<td>Observational data suggest incidence of TMA in patients with HIV historically was 7% [160] and 35% if AKI [161], but has markedly reduced in HAART era to 0.3% [162].</td>
</tr>
<tr>
<td>CMV</td>
<td>No evidence.</td>
<td>Case report of de novo TMA after kidney transplant in the context of CMV infection, and recurrence of TMA with recurrence of CMV viraemia in the absence of CNI; successfully treated with valganciclovir and eculizumab [163].</td>
<td>No evidence.</td>
</tr>
<tr>
<td>BMT</td>
<td>Mouse models: evidence that conditioning for BMT with radiation activates complement [164, 165] and treatment with a C5aR inhibitor reduced GvHD morbidity [165].</td>
<td>Use of eculizumab:</td>
<td>• Review of 5423 published cases: response to PEX reported in 0–80%, but mortality in those treated with PEX was 44–100% [181].</td>
</tr>
<tr>
<td></td>
<td>Observational clinical data:</td>
<td></td>
<td>• American Society for Apheresis guidelines: &gt;300 reported patients (no trials): grade 2C, category III recommendation for PEX [109].</td>
</tr>
<tr>
<td></td>
<td>• Kidney C4d deposition in TMA in context of GvHD [166, 167].</td>
<td></td>
<td>• Mortality 50–60% despite treatment, with death due to complications of renal failure or GvHD, or infection [182].</td>
</tr>
<tr>
<td></td>
<td>• Proteinuria (&gt;30 mg/dL) and elevated sC5b-9 associated with poor survival [168].</td>
<td></td>
<td>• 20% response rate to PEX [173].</td>
</tr>
<tr>
<td></td>
<td>• Normal C3 and C4 levels [169].</td>
<td></td>
<td>• Response rate to PEX 55%, but mortality 80% [175].</td>
</tr>
<tr>
<td></td>
<td>Genetics:</td>
<td></td>
<td>• Retrospective analysis of 11 cases: treatment was with CNI withdrawal and PEX: 64% responded, but mortality 38% (versus 13% without TMA) [183].</td>
</tr>
<tr>
<td></td>
<td>• Heterozygous CFHR1/3 and CFHR1/4 deletion and detectable Anti-FH Ab [170].</td>
<td></td>
<td>• Case reports of some response to rituximab, but mortality still high [184, 185].</td>
</tr>
<tr>
<td></td>
<td>• Genetic analysis of 34 patients with TMA after BMT: multiple complement gene variants of uncertain significance reported [171].</td>
<td></td>
<td>• Case series of 7 patients with severe hypertension and TMA treated with anti-hypertensive medication: TMA resolved in all [190].</td>
</tr>
<tr>
<td>Severe hypertension</td>
<td>Mouse model of angiotensin II-induced hypertension: C5aR knock-out mice exhibited reduced cardiac remodelling and inflammation [186] and a C5aR antagonist reduced cardiomyocyte hypertrophy, cardiac inflammation and perivascular fibrosis [187].</td>
<td>No evidence.</td>
<td>• Literature review: 19 cases with severe hypertension and TMA; all were treated with anti-hypertensive medication and 1/3 also had PEX: symptomatic improvement 100%, thrombocytopenia improvement in 84%, but significant sCr improvement in only 58% [191].</td>
</tr>
<tr>
<td></td>
<td>Observational clinical data: longitudinal cohort study (2178 males): higher plasma C3 levels associated with development of hypertension [188].</td>
<td></td>
<td>• Case report: complete recovery of TMA and PRES with anti-hypertensive medication [192].</td>
</tr>
<tr>
<td></td>
<td>Genetics: population-based cohort study (3210 individuals): CFHR3/1 deletion and an AMD related CFH SNP were significantly associated with hypertension risk [189].</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
</table>
| Drug mediated | • Genetics: CFH variants in 4 patients with ticlopidine-associated TMA (all had ADAMTS13 < 5%) [193].
• Case report: low C3 in a patient with clopidogrel-associated TMA (no genetic analysis) [194].
• Case reports/series of eculizumab: Successful use reported in TMA associated with mitomycin C [195], gemcitabine [196–198], though given concurrently with other treatment (such as drug withdrawal, PEX); despite TMA response prognosis still poor due to malignancy [198].
• 1 patient with proteasome inhibitor associated TMA had persistent TMA after eculizumab and died [199].
• American Society for Apheresis guidelines: Based on available evidence (no trials, only case series and reports) PEX recommended for ticlopidine-associated TMA (which should be considered TTP due to ADAMTS13 deficiency) but for all other drug-associated TMA the role of PEX has not been established and may be harmful [109].
• 7 patients with TMA associated with ticlopidine and ADAMTS13 deficiency: all recovered with PEX and drug discontinuation [200].
• Review of 44 patients with gemcitabine-associated TMA: worse outcome with PEX than drug withdrawal alone [201].
• Case series of 10 patients thought to have TMA with malignancy: all died despite supportive care and drug discontinuation [203].
| Malignancy associated | No evidence. Case reports of eculizumab use are all in the context of chemotherapy—see above.
• Case reports of eculizumab use in 10 patients thought to have TMA with malignancy (all received chemotherapy) demonstrated some benefit with PEX [203].
• Registry report: 85 cases with malignancy-associated HUS. 99% received mitomycin C, 80% received 5-FU. 30% said to respond to PEX [204].
• Registry report: 20 cases with malignancy-associated HUS. 50% 30-day mortality; chemotherapy associated with better outcome than PEX/PI [205].
| Autoimmune condition/glomerulopathy associated | No evidence.
• Case reports of successful use of eculizumab in SLE with TMA (but no APS) [209–213].
• Historical outcomes: in a review of 56 published cases of SLE with 'TTP' (prior to ADAMTS13 availability) mortality was 34%: 32% in PEX group versus 44% without PEX [214].
• No RCTs.
• A prospective, single-arm, phase 2 trial is ongoing (eculizumab to enable renal CAPS registry: 522 episodes. Most frequent treatment was AC + GC (19%) or AC + GC + PEX 6 IVIG (18%); only 0.2% received (continued)
Table 1. Evidence for complement involvement in pathogenesis

<table>
<thead>
<tr>
<th>TMA</th>
<th>Evidence for complement involvement in pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Complement-dependent and complement-independent pathways in a mouse model of TMA induced by aPL Ab [215].</td>
<td>transplantation in patients with history of catastrophic antiphospholipid antibody syndrome. ClinicalTrials.gov Identifier: NCT01029587.</td>
<td>eculizumab. Overall mortality 37% (no subgroup analysis according to treatment modality) [232].</td>
<td>• In kidney transplant recipients with APS: 7/10 treated with sirolimus had a functioning graft 144 months after transplantation versus 3/7 untreated patients [233].</td>
</tr>
<tr>
<td>• Passive transfer of human an aPL Ab: complement activation plays a role in fetal loss and tissue injury [216].</td>
<td>• Case reports/series of successful use of eculizumab: CAPS [223–228].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Factor B inhibitor prevented aPL Ab-induced pregnancy loss [217].</td>
<td>CAPS recurrence in renal transplant [229, 230].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• C5 inhibitor iE576 inhibits in vivo effects of aPL Ab [218].</td>
<td>Prophylactic anticoagulation and eculizumab to enable renal transplantation in 3 patients [231].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation clinical data in APS:</td>
<td>3 cases with recurrence after kidney transplant: TMA resolved with eculizumab but chronic APS nephropathy not prevented [219].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• C5b-9 and C4d deposition in kidney allografts with TMA due to APS recurrence [219].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• (Not specific to APS with TMA): low C3 and C4, high C3a [220] and low C3 and C4 more frequent if renal involvement [221].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>anti-FH Ab in patients with APS, and association with VTE recurrence [222].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgA nephropathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation clinical data:</td>
<td>Trial ongoing (not in patients with TMA): open label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA nephropathy on stable RAAS blockade. ClinicalTrials.gov Identifier: NCT02384317.</td>
<td>No evidence specific to IgA nephropathy with TMA.</td>
<td></td>
</tr>
<tr>
<td>• Mesangial C3 deposition in ~90% of patients [234].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Glomerular deposition of MBL [235–237] observed, and associated with more severe renal disease [238].</td>
<td>• 2 case reports of use of eculizumab for crescentic IgA nephropathy with TMA: transient response, but did not prevent progression to ESR [242, 243].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Normal FH levels and no mutations in CFH exons 18–23 in 46 patients [234].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Low FH levels associated with IgA nephropathy in 2 families [239].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetics:</td>
<td>RCT of CCX168 (C5aR inhibitor) plus standard of care in AAV: results awaited. ClinicalTrials.gov Identifier: NCT02222155 (not specific to cases with TMA).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• GWAS identified association between CFHR3/1 deletion (protective) and IgA nephropathy [240].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rare variants in CFHR5 may contribute to genetic susceptibility to IgA nephropathy [241].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANCA-associated vasculitis</td>
<td>Mouse models suggest complement important in pathogenesis of AAV [244, 245] and C5aR blockade protects against AAV [246].</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observation clinical data:</td>
<td>RCT of CCX168 (C5aR inhibitor) plus standard of care in AAV: results awaited. ClinicalTrials.gov Identifier: NCT02222155 (not specific to cases with TMA).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Hypocomplementaemia in AAV associated with concurrent TMA and higher mortality [247] and poor renal prognosis [248].</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Majority of AAV renal biopsies are negative for immune complexes but are positive for C3d, C4d and C5b-9 staining [249].</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

No trials specific to AAV with TMA. | |
In AAV RCTs have demonstrated efficacy of cyclophosphamide and rituximab [250, 251]. | | |

(continued)
<table>
<thead>
<tr>
<th>TMA Evidence for complement involvement in pathogenesis</th>
<th>Evidence for complement-targeted therapy</th>
<th>Evidence for other management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Membranous</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat model of MN: C3 and C5b-9 co-localize with immune deposits, and urinary podocytes are coated in C5b-9 [252].</td>
<td>In vitro: anti-PLA2R IgG4 autoantibodies from MN patients can bind to C4 via MBL [252].</td>
<td>Observational clinical data: glomerular deposition of FH and C3b [253], MBL and C5b-9 [254], and urinary C5b-9 excretion predicts poor prognosis [255].</td>
</tr>
<tr>
<td>No evidence specific to MN with TMA.</td>
<td>No trials specific to MN with TMA.</td>
<td>No evidence to date on TMA targets for other management.</td>
</tr>
<tr>
<td>RCT in MN demonstrated efficacy versus placebo in reducing serum creatinine in MN patients with TMA [256].</td>
<td>Case report of 200 patients with TMA treated with eculizumab: no evidence of efficacy [252].</td>
<td>Case reports/series of MN with TMA describe some response to FFP [257]; rituximab [258], together with corticosteroids [259] and PEX [260].</td>
</tr>
<tr>
<td><strong>FSGS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observational clinical data: raised plasma and urine Ba, C4a, sC5b-9 levels [261].</td>
<td>Combined IgM and C3 glomerular deposition was an independent risk factor for inferior treatment responses and worse renal outcomes [262].</td>
<td>Case report: no response to eculizumab in a patient with TMA and INF2 mutation [263].</td>
</tr>
<tr>
<td>No evidence specific to FSGS with TMA.</td>
<td>No trials specific to FSGS with TMA.</td>
<td>No trials specific to FSGS with TMA.</td>
</tr>
<tr>
<td><strong>SRC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peritubular capillary C4d score associated with non-recovery of renal function [264].</td>
<td>C5b-9 deposition detected in skin biopsies of SSc patients but not in healthy subjects [265].</td>
<td>Case reports of eculizumab use: SRC with TMA in pregnancy; low C3 and C4, high C5b-9, no complement mutations. Management was Caesarean and AEC inhibitors/Plasminogen activator inhibitor-1 [266].</td>
</tr>
<tr>
<td><strong>MPGN/C3G</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse model of MPGN: lower creatinine and reduced mortality in C5–/– mice [270].</td>
<td>In vitro: functional studies of anti-FH Ab; different binding epitopes compared with aHUS [34].</td>
<td>Case report: no response to eculizumab in 3 cases of SRC and TMA treated with PEX in addition to ACE inhibitors [269].</td>
</tr>
<tr>
<td>Observational data: the use of ACE inhibitors has reduced mortality from 85% at 6 months to 25–35% [288].</td>
<td>Genes: complement gene mutations in 17–20% [271, 272].</td>
<td>Case reports/series (not specific to cases with TMA) have reported partial [276, 277] and good response to eculizumab in native kidneys [278–286] and in transplant recurrence [287, 288].</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speculation about use of eculizumab [289].</td>
</tr>
</tbody>
</table>

**DIC** No evidence. Speculation about use of eculizumab [289].

**DIC** Disseminated intravascular coagulation; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3Nef, C3 nephritic factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephropathy; aHUS, atypical hemolytic uremic syndrome; aPL, antiphospholipid syndrome; C3RF, complement C3-related factor; DDD, dense deposit disease; C3G, C3 glomerulopathy; C5RF, C5 nephritic factor; FFP, fresh frozen plasma; AMD, age-related macular degeneration; SNP, single nucleotide polymorphism; PRES, posterior reversible encephalopathy syndrome; GWAS, genome-wide association study; AC, anticoagulation; GC, glucocorticoids; AAV, ANCA-associated vasculitis; MN, membranous nephro
outcomes with CNI withdrawal, with and without PEX, have been described in case reports and series [72, 74, 75]. A small number of case reports describe good outcomes with eculizumab for de novo TMA after kidney [67, 68] and simultaneous pancreas and kidney (SPK) [69–71] transplantation, but in all cases this was in combination with other strategies such as immunosuppression alteration and PEX. De novo TMA has also been reported to occur in 4% of liver transplant recipients and 2.3% of lung transplant recipients; the cause again is likely to be multifactorial [297].

For those carrying a complement mutation where the initial diagnosis may not have been made there is a clear rationale for eculizumab. In those without underlying complement abnormalities, the role of eculizumab is less clear and in many cases removal of CNIs or treatment of viral infections is sufficient to stop the TMA. Despite this, evidence of complement activation can be seen in these scenarios and it is unclear whether eculizumab would have an additional benefit to removal of the offending stimuli.

**Antibody mediated rejection**

TMA can manifest in the context of AMR; it was observed in 13.6% of C4d-positive biopsies in one large retrospective study [298]. There is no evidence for the role of complement in AMR triggering a TMA. The deposition of C4d in peritubular capillaries suggests classical complement pathway activation [76], though this feature is not requisite for the diagnosis of AMR according to the 2013 Banff criteria [299]. Therapeutic strategies for AMR (not specific to AMR with TMA) include PEX, intravenous immunoglobulin (IVIG) and rituximab, but there is insufficient evidence to determine the optimal treatment [92]. A trial of eculizumab for treatment of AMR was negative (unpublished; NCT01895127) and a non-randomized trial of eculizumab in sensitized recipients found that acute episodes were reduced but not chronic AMR [81]. Case reports of eculizumab for AMR with [77, 79, 80, 278] and without [84–91] TMA describe both good and poor outcomes. In summary, further research is required to define the role of eculizumab in TMA associated with AMR.

**DGKE-mediated renal disease**

Recessive mutations in the DGKE gene causing TMA were first reported in 2013 [94]. Genetic pleiotropism is also seen in DGKE-mediated renal disease with a separate report describing a membranoproliferative glomerulonephritis-like disease [300]. In vitro experiments suggest that the development of TMA due to loss of DGKE expression or activity is independent of complement activation [93]. Data regarding outcomes and treatment response are limited. Good outcomes have been reported with supportive treatment and PEX or plasma infusion [96, 97], but in the largest published cohort all patients developed progressive chronic kidney disease (CKD) or ERF regardless of treatment, and the single patient who received eculizumab relapsed on treatment [94]. One child with a DGKE mutation in the paediatric eculizumab trial did respond [39, 291] although given the relapsing/remitting nature of DGKE-mediated disease, attributing efficacy is difficult. In a separate case report of eculizumab response, the patient had a concomitant C3 mutation [95]. More data are required before the role of complement in the pathogenesis of DGKE-mediated aHUS and thus eculizumab treatment can be defined.

**Methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type**

Homozygous or compound heterozygous mutations in the MMACHC gene result in a disorder of cobalamin (cbl; vitamin B12) metabolism. The severity of phenotype may vary but includes developmental, ophthalmological, neurological, cardiac and renal manifestations. TMA is associated with MMACHC mutations although the pathophysiological mechanisms that result in endothelial damage are unclear [129]. It can present in childhood or adulthood, and prognosis is very poor if untreated or if there is cardiopulmonary involvement; however, metabolic therapy with hydroxycobalamin is very effective [129]. The role of complement is not clear; there are isolated reports of concomitant complement gene mutations and polymorphisms that may modify the disease [129–131], but the small number of published reports of eculizumab use describe non-response [129, 132]. As such, treatment with metabolic therapy remains the gold standard.

**Thrombotic thrombocytopenic purpura**

TTP is a disorder mediated by deficiency of ADAMTS13, a von-Willebrand factor (VWF)-cleaving protease, which can be hereditary (ADAMTS13 mutations) or acquired (anti-ADAMTS13 autoantibody), and is characterized by unusually large VWF multimers and consequent occlusive microvascular platelet aggregation [22]. There is some evidence of complement involvement in a mouse model [98] and in vitro [99], and observational clinical data suggesting that the alternative complement pathway is activated [98, 100–103] (Table 1). One study analysed the complement genetics in patients with TTP and found no mutations [104]. The advent of PEX in the treatment of TTP decreased mortality to <10% from essentially universal fatality and numerous RCTs demonstrate its efficacy [109], and rituximab rituximab reduces the relapse rate in acquired TTP [110–112]. PEX is unquestionably the first-line treatment in TTP and should be instituted urgently once the diagnosis is suspected. There is speculation about an adjuvant role for complement inhibiting therapy in severe TTP [301], but there is only a single case report that describes a response to eculizumab in a patient with TTP and no complement mutation or FH autoantibody [108], so currently there is no evidence to support this.

**Pregnancy-associated TMAs**

**Pregnancy-associated complement-mediated aHUS**

Pregnancy appears to be the trigger for complement-mediated aHUS to manifest in ~20% of women, and this usually presents in the post-partum period [302]. In a pregnancy-associated aHUS cohort, complement mutations were identified in 86%, and though a high proportion were treated with PEX, 76% developed ERF [303]. Pregnancy-associated complement-mediated aHUS was not included in the initial trial of eculizumab, although good outcomes have been published in case reports [116, 117]. Given that pregnancy-associated aHUS appears to have a high incidence of complement mutations there is a good rationale for complement inhibition and, based on this, the authors’ opinion is that pregnancy-associated complement-mediated aHUS should be treated with eculizumab.

**Pregnancy-associated TTP**

It has been reported that 10–36% of women with TTP present during pregnancy [304], particularly during the second or third trimesters [303]; in normal pregnancy, there is increased release
of VWF, which consumes ADAMTS13, therefore its activity falls, and in women with a genetic predisposition it can fall low enough for TTP to manifest [303]. There is no evidence regarding complement and complement therapeutics in pregnancy-associated TTP.

 Syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP)
The HELLP syndrome is a TMA-like syndrome that occurs in 0.5–0.9% of all pregnancies, and complicates 5–10% of cases of severe pre-eclampsia [124]. The pathogenesis is poorly understood, though there is some evidence suggesting an association with increased circulating levels of the syncytiotrophoblast-derived angiogenic factors soluble endoglin and the soluble form of the vascular endothelial growth factor (VEGF) receptor (sFlt-1) [305, 306]. Unlike pregnancy-associated complement-mediated aHUS only a minority (8–10%) of patients with pre-eclampsia and HELLP syndrome harbour complement genes variants, mostly of unknown significance or non-pathogenic [125]. There is some observational data that suggests the alternative complement pathway is activated in HELLP [119] and pre-eclampsia [120, 121], and in vitro, eculizumab added to HELLP serum resulted in reduced cell killing [118]. Complete biochemical resolution has been observed with expectant management, which includes bed rest, sodium-restricted diet, antihypertensive treatment, anticonvulsant treatment and non-invasive monitoring, but fetal mortality is high [128]. The use of eculizumab (in addition to expectant management) to delay delivery in a patient with HELLP has been reported [128]. However, it is notable that in a cohort of women with PNH taking eculizumab, 8% still developed pre-eclampsia [126], and in a small case series of women with complement-mediated aHUS, both pre-eclampsia and HELLP occurred despite ongoing eculizumab treatment during pregnancy [127]. Although it is possible that complement does play a role in HELLP pathogenesis, the current available evidence does not support the use of complement-inhibiting therapy.

Infection associated
STEC-HUS
In STEC-HUS endothelial damage occurs following ribosomal inactivation, and inhibition of protein synthesis by Shiga toxin, which enters the cells after binding to the Gb3 receptor [22, 307]. In addition, Shiga toxin can activate signalling pathways inducing an inflammatory response in affected cells [308]. The prognosis is good compared with that of most other TMs; long-term outcome data suggest that 70% fully recover, 3% develop ERF and 9–18% develop CKD [150], and it is considered to be a self-limiting condition.

There is evidence suggesting that the lectin [134] and alternative [133, 135, 138, 139] complement pathways are activated or dysregulated [137] in in vitro and animal models of STEC-HUS [309]. In patients with STEC-HUS, increased levels of C5b-9 have been observed, suggesting that the terminal pathway is activated [140–142]. However, mutations in complement genes are only rarely detected in these patients, and in these cases the clinical picture is unusually severe [21, 140, 143–146].

A small case series published in 2011 first reported full renal and neurological recovery in three children with severe disease who were treated with eculizumab [149]. Subsequently, in the 2011 O104:H4 outbreak in Europe, which was characterized by severe disease in adults as well as children, a significant proportion were treated with eculizumab. The retrospective analyses did not demonstrate a beneficial role of eculizumab or PEX over supportive care [147, 148, 153], though direct comparison is difficult because the patients who were treated with eculizumab had more severe disease. A further case series of eculizumab use in STEC-HUS with neurological involvement has been published [310], and many unanswered questions remain regarding any potential role [311]. An RCT of eculizumab for STEC-HUS in children is ongoing (NCT02205541) and in such a self-limiting illness only this will define the role of complement inhibition.

Pneumococcal HUS
TMA is reported in association with Streptococcus pneumoniae infection; a hypothesized mechanism is that neuraminidase produced by pneumococci cleaves sialic acid residues from glycoproteins on erythrocyte, platelet and endothelial cell membranes, exposing the cryptic Thomsen-Friedenreich antigen (T-antigen) to which IgM in the plasma can then bind, resulting in cell damage and TMA [158]. Pneumococcal HUS is therefore Coombs test positive. The natural history is of poor prognosis, with high morbidity and mortality [312–315], usually reflecting the severity of the infection [155]. The role of complement is unclear although transient low serum C3 levels [156, 157] and rare complement gene mutations [129] have been reported. There is also speculation that neuraminidase may induce a functional FH deficit [155, 316]. A single case report describes a good outcome in a child treated with eculizumab after poor response to supportive care [156]. Currently, there is insufficient evidence to recommend eculizumab treatment in a situation where there is active infection.

HIV
Prior to the advent of highly active anti-retroviral therapy (HAART), TMA was not uncommon in people with HIV infection [317]: incidences of 7% [160], and 35% in those with AKI [161], have been reported. The pathogenic mechanisms remain undefined, despite investigation in Macaque models of HIV-associated TMA [318]. With the introduction of HAART the incidence has fallen to 0.3% [162]. There is a single case report describing good outcome with eculizumab in an individual who had been non-compliant with HAART, presumably concurrently with the reintroduction of anti-retrovirals [159]. Again, treatment of the underlying infection should remain the mainstay of treatment.

Bone marrow transplant-associated TMA
A multisystem TMA complicates 10–20% of allogeneic bone marrow transplants (BMTs) [175] although individual centres have reported an incidence as high as ~40% [171]. There are multiple risk factors, including CNIs, graft versus host disease (GVHD), HLA mismatch, chemotherapy, radiation therapy and infections [319]. In common with solid organ transplantation, it is likely that these factors contribute to an endothelial-damaging milieu. Prognosis is very poor, with mortality rates variously reported at 21–75% [168, 169, 181, 183]. There has been much interest in the possible role of complement. Mouse models suggest that complement is activated during radiation conditioning [164, 165] and observational data in humans suggest that complement may be activated [166–168]. Rare functionally significant variants in known aHUS-associated complement genetic risk factors [171] and factor H autoantibodies [170] have been reported rarely. There is no evidence that PEX results in reduced mortality [175, 181, 183] and its role has not been established [109]. There are no prospective trials of complement inhibiting therapy. In the largest retrospective analysis, 1-year survival (62%) was favourable in those treated with
eculizumab compared with historical controls [172]. In some case series and reports, mortality has been high despite a haematological response [179, 180], though in others the outcome was good [175–178]. Trial evidence will likely be required before a consensus on the role of complement-inhibiting therapy can be achieved.

Severe hypertension

Case series of patients with severe hypertension have identified TMA in 27–44% [190, 320–322]. The pathophysiology of severe hypertension is complex and not completely understood, and the role of complement has not been fully defined [323, 324]. Conversely, any patient with a TMA may have severe hypertension, and distinguishing between severe hypertension-associated TMA and complement-mediated aHUS at the time of the acute presentation to guide appropriate management strategy is a major challenge. In a retrospective case series, genetic analysis identified rare variants in complement genes in patients in whom TMA was initially attributed to severe hypertension; eight of nine patients progressed to ERD despite management of hypertension [324]. However, in the majority of patients with TMA associated with severe hypertension, renal function and microangiopathic haemolytic anaemia (MAHA) usually recover with the management of blood pressure [323, 325] and therefore in practice the failure of the TMA to respond to blood pressure control often informs the diagnosis and future investigation and management.

Drug-mediated TMA

There are many published reports that describe drug-mediated TMA, either by acute, immune-mediated reactions [326] or by dose-dependent toxicity [327–329]. A systematic review in 2015 found evidence of a definite association in only 28% of the 78 drugs reported, the most common of which included quinine (immune mechanism) and ciclosporin, tacrolimus, sirolimus and interferon, and chemotherapy agents such as gemcitabine and mitomycin (toxic mechanism) [326]. There is no strong evidence for the role of complement, and recovery has been reported following drug withdrawal [201, 202]. The only recognized role for PEX is in ticlopidine-associated TMA, which is associated with severe ADAMTS13 deficiency [109].

Malignancy-associated TMA

TMA can manifest in malignancy, though it can be challenging to differentiate between chemotherapy-induced TMA and malignancy-induced TMA [330]. One proposed mechanism for TMA is erythrocyte shearing following direct contact with microvascular embolic tumour cells [203, 331, 332], and when TMA is associated with disseminated malignancy the prognosis is predictably very poor regardless of treatment strategy [203–205].

Complement factor H autoantibodies have also been associated with malignancy, although not in the setting of TMA [333]. Case reports of eculizumab use in patients with cancer and treated with chemotherapy agents have suggested a TMA response [195–198], though in most cases the eculizumab was concurrent with drug withdrawal or PEX.

TMAs associated with glomerular diseases

Focal segmental glomerulosclerosis (FSGS) and INF2-mediated renal disease

TMA has been reported in patients with primary FSGS [258, 334–336], and FSGS is a frequent pathological sequela of STEC-HUS [337]. There is some observational data suggesting that complement is activated in FSGS [261] and may be associated with worse outcomes [262]. Mutations in INF2 are the most common cause of familial autosomal dominant nephrotic syndrome; however, more recently it has also been associated with TMA [263]. In this report, all individuals with INF2 mutations presenting with a TMA also had complement-mediated aHUS risk haplotypes, potentially accounting for the genetic pleiotropy. Despite this eculizumab was ineffective in controlling the TMA, suggesting that the mechanism is not dependent on the terminal pathway of complement.

IgA nephropathy

Histopathological evidence of TMA has been reported in 2.3–53% [338, 339] of IgA nephropathy biopsies although few also had laboratory evidence of MAHA. In those with TMA a very high proportion had uncontrolled hypertension, so it is difficult to distinguish between TMA associated with severe hypertension and TMA associated with IgA nephropathy. There is some evidence that complement genetics are associated with IgA nephropathy: CFHR3/1 deletion may be protective [240, 340] and CFHR5 rare variants may contribute to genetic susceptibility [241]. Mesangial C3 deposition is seen in ~90% of patients [234], and deposition of MBL suggests the lectin pathway may be activated [235–237] and associated with more severe disease [238].

Two case reports describe the use of eculizumab for crescentic IgA nephropathy with TMA: there was a transient response, but it did not prevent progression to ERD [242, 243]. A single-arm trial of the C5a inhibitor CCX168 in IgA nephropathy (not restricted to cases with a TMA) is ongoing, but there is currently not strong evidence for complement-inhibiting therapy in cases with a TMA.

ANCA-associated vasculitis

Histopathological evidence of TMA has also been reported to occur in 14% of ANCA-associated vasculitis (AAV) biopsies [341], again without laboratory evidence of MAHA. Prognosis among those with concomitant TMA is poor: death or ERD occurs in up to 60% [258]. Mouse models suggest that complement is important in pathogenesis [244, 245] and C5aR blockade is protective [246]. In humans, the majority of AAV biopsies show deposition of C3d, C4d and C5b-9 [249], and hypocomplementaemia is associated with higher mortality [247] and worse renal prognosis [248].

There are no published reports of complement-inhibiting therapy in patients with AAV and TMA. An RCT of the C5aR inhibitor CCX168 in AAV (not restricted to cases with TMA) is ongoing.

Membranous nephropathy

There are case reports of TMA occurring with membranous nephropathy [257–260, 342, 343]. There is strong evidence that complement is activated in membranous nephropathy: in rat models [252], in vitro (lectin pathway) [252] and in observational clinical studies [253–255]. There is no evidence regarding management specific to membranous nephropathy with TMA, but an early trial of eculizumab in membranous nephropathy (presented in abstract form but never published) [252] was negative, though dosing was inadequate and follow-up was short.

C3G/mesangioproliferative glomerulonephritis with TMA

Both C3G and mesangioproliferative glomerulonephritis (MPGN) are complement-mediated diseases with autoimmune (C3 nephritic factor, factor H autoantibodies) and inherited (CFH, C3, CFHRs mutations) complement abnormalities [344–348] underlying many cases. Despite the role of complement in C3G, in a small
single-arm trial of eculizumab in C3G not all patients responded [273], potentially suggesting a role of complement downstream of C5. Concurrent [258, 275, 349, 350] and sequential [351] manifestation of C3G and TMA has been reported. There is one case report of MPGN with TMA describing TMA resolution with eculizumab [274]. Despite the lack of efficacy of eculizumab in C3G where the presentation is nephrotic syndrome, given that C3G and complement-mediated aHUS share many of the same complement autoimmune and genetic predispositions it seems likely that eculizumab would have a role where a TMA supervenes, though definitive evidence is not available.

**TMAs associated with autoimmune conditions**

**Systemic lupus erythematosus**

Concurrent TMA has been observed in 8–15% of systemic lupus erythematosus (SLE) biopsies and was reported to have no influence on outcome [352, 353] in some cohorts, but was associated with worse renal outcome in another [354]. In a mouse model of SLE, C5 inhibition increased survival [206]; in humans hypocomplementaemia correlates with disease activity [207], and CFHR3/1 deletion is associated with susceptibility to SLE [208]. Successful use of eculizumab for SLE with TMA has been published in case reports [209–213], but the only trial of eculizumab in SLE to date is a phase 1 study [207].

**Antiphospholipid syndrome**

The catastrophic antiphospholipid syndrome (CAPS) international registry reports the incidence of TMA to be 14% [232]. In a mouse model of antiphospholipid antibody (aPL Ab)-mediated TMA both complement-dependent and complement-independent pathways were described [215] and C5 blockade inhibited in vivo effects of aPL Ab [218]. There is observational data in humans suggesting that complement is activated [219–221]. Case reports and series describe the successful use of eculizumab for CAPS in native kidneys [223–228] and transplant kidneys [229–231]. There are no RCTs of complement-inhibiting therapy but the evidence supports the rationale, and a prospective, single-arm trial of eculizumab to enable renal transplantation in CAPS is ongoing (NCT01029587).

**Scleroderma renal crisis**

Scleroderma renal crisis (SRC) occurs in ~10% of people with systemic sclerosis, and TMA manifests in 45–50% [355]. The use of angiotensin-converting enzyme (ACE) inhibitors has transformed prognosis: from ~85% mortality at 6 months to 25–35% [268]. There is no strong evidence that complement is involved in the TMA. In two case reports eculizumab was used in addition to ACE inhibitors: there was haematological response in both, though one died [266, 267].

**Summary**

Ensuring that complement inhibitory therapy is used appropriately is critically important, principally to avoid exposing patients unnecessarily to the risks of terminal complement inhibition, but the financial implications to health services (eculizumab costs £327 600 per person per year in the UK [356]) also need to be considered.

In addition to its central role in the pathogenesis of complement-mediated aHUS, complement activation is seen in many other forms of TMA. Despite this, it is unclear if this is the primary event, a modifying event or has no contribution to the TMA whatsoever.

Although the seminal trial of eculizumab did not use a control arm to demonstrate efficacy, the high historical morbidity and mortality of aHUS in individuals with complement abnormalities suggested effectiveness. For other cases of TMA, the evidence for utility of eculizumab comes mainly from case reports with the inherent publication bias. Additionally, interpretation of available data in other TMAs is difficult because: some disorders are self-limiting (e.g. STEC-HUS); some have a clear precipitant that can be treated/removed (e.g. severe hypertension and drug-mediated TMA); some are complex and multifactorial (e.g. TMAs occurring after bone marrow or solid organ transplantation); and in some the prognosis of the underlying disorder may be very poor (e.g. TMA associated with disseminated malignancy).

For those individuals with an established complement-mediated aHUS (mutation or autoantibody), treatment is not informed by RCTs, and while the current recommendation is for lifelong treatment with eculizumab there is no evidence that this is necessary. Research is needed to determine who can stop it and when, as well the appropriate monitoring strategy. A number of cases of eculizumab withdrawal have been published [23], and Alexion Pharmaceuticals are collecting data on individuals in whom eculizumab is stopped (EVIDENCE observational study), a trial is being conducted in France (NCT02574403) and a prospective trial of eculizumab withdrawal in complement-mediated aHUS is under way in the UK.

In summary, further research is needed to define the role of complement in the spectrum of TMAs, and complement C5-inhibiting therapy should not be considered a panacea.

**Funding**

V.B. has received funding from the Northern Counties Kidney Research Fund and is a Medical Research Council/Kidney Research UK Clinical Research Training Fellow. The research leading to these results has received funding from the European Union’s Seventh Framework Programme (FP7/2007–2013) under Grant 305608 (EURENOMICS), The Wellcome Trust (095884/Z/11/Z), The Medical Research Council and the Northern Counties Kidney Research Fund.

**Conflict of interest statement**

D.K. has received honoraria for consultancy work from Alexion Pharmaceuticals, and is a director of and scientific advisor to Gyroscope Therapeutics.

**References**

29. Ferreira VP et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009; 182: 7009–7018
42. Sheerin NS et al. A national specialized service in England for atypical haemolytic uraemic syndrome—the first year’s experience. QJM 2016; 109: 27–33
Complement C5-inhibiting therapy for the TMAs


252. Fukui S et al. Antineutrophil cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine (Baltimore) 2016; 95: e4871


301. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. *Nat Rev Nephrol* 2012; 8: 622–633


311. Trachtman H et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. *Nat Rev Nephrol* 2012; 8: 658–669


328. Hunt D

329. Eremina V

330. Kavanagh D et al

331. Al-Nouri ZL


333. Amornsiripanitch N

334. Chang A


